By Elric Langton | 18th November 2021
Poolbeg Pharma (AIM: POLB), a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, is pleased to update the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza.
The Company intends to commence the Phaβ¦